Analyte Sensor, and Associated System and Method Employing a Catalytic Agent

• US 20130006079A1
• Filed: 04/02/2012
• Published: 01/03/2013
• Est. Priority Date: 02/09/2004
• Status: Active Grant

• Current Assignee: Abbott Diabetes Care Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: Abbott Diabetes Care Incorporated (Abbott Laboratories Incorporated)
• Inventors: Feldman, Benjamin J., Liu, Zenghe, Cohen, David C., Heller, Adam
• Granted Patent: US 8,761,857 B2
• Time in Patent Office: Days
• US Class Current: 600/345
• CPC Class Codes: A61B 5/14514 using means for aiding extraction of interstitial fluid, e.g. microneedles or suction
• CPC Class Codes: A61B 5/14528 invasively
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61B 5/14865 invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
• CPC Class Codes: A61B 5/686 Permanently implanted devices, e.g. pacemakers, other stimulators, biochips A61B5/6861 takes precedence
• CPC Class Codes: C12Q 1/002 Electrode membranes
• CPC Class Codes: C12Q 1/004 mediator-assisted
• CPC Class Codes: C12Q 1/005 involving specific analytes or enzymes including groups of enzymes, e.g. oxydases; C12Q1/004 takes precedence
• CPC Class Codes: C12Q 1/006 for glucose

Abstract

An analyte sensor for use in connection with a biofluid is described. The analyte sensor may comprise any suitable interface between the biofluid and a derivative of the biofluid and any suitable transducer of information concerning an analyte. At least one catalytic agent is provided in a locale or vicinity of the interface. The catalytic agent, such as a proteinaceous agent or a non-proteinaceous, organic-metal agent, is sufficient to catalyze the degradation of reactive oxygen and/or nitrogen species that may be present in the vicinity of the interface. An analyte-sensing kit and a method of sensing an analyte are also described.

Claims

1-31. -31. (canceled)

32. A method of sensing an analyte in a derivative portion of a biofluid, comprising:

passing a biofluid through an interface to produce a derivative portion of the biofluid, wherein the interface comprises;

an organic-metal catalytic agent sufficient to catalyze the degradation of at least one of a reactive oxygen species and a reactive nitrogen species of biological origin in at least one of the biofluid and the derivative portion of the biofluid, the agent selected from a a proteinaceous catalytic agent, a non-proteinaceous catalytic agent, or any combination thereof;

contacting the derivative portion of the biofluid with a transducer sufficient for generating a signal that corresponds to a concentration of an analyte; and

generating a signal that corresponds to a concentration of the analyte in the derivative portion of the biofluid.

33. The method of claim 32, wherein the interface comprises a cutaneous port.

34. The method of claim 33, further comprising forming the cutaneous port.

35. The method of claim 34, wherein said forming comprises ultrasonically disrupting a portion of skin.

36. The method of claim 34, wherein said forming comprises iontophoretically drawing the derivative portion of the biofluid out of a portion of skin.

37. The method of claim 34, wherein said forming comprises photothermally disrupting a portion of skin.

38. The method of claim 34, wherein said forming comprises propelling at least one particle into a portion of skin.

39. The method of claim 38, wherein the catalytic agent is associated with the at least one particle.

40. The method of claim 33, wherein the catalytic agent is topically provided in the locale of the cutaneous port.

41. The method of claim 33, wherein the catalytic agent is sprayed onto the locale of the cutaneous port.

42. The method of claim 32, wherein the interface comprises a synthetic membrane.

43. The method of claim 42, wherein the catalytic agent is associated with the synthetic membrane.

44. The method of claim 42, wherein the catalytic agent is covalently associated with the synthetic membrane.

45. The method of claim 32, wherein the catalytic agent is an agent of biocompatibility.

46. The method of claim 32, wherein the catalytic agent is an agent of signal quality.

47. The method of claim 32, wherein the catalytic agent is an anti-neutrophilic agent.

49. The method of claim 32, wherein generating a signal comprises oxidizing the analyte at the transducer with an analyte-responsive enzyme.

50. The method of claim 49, wherein the analyte-responsive enzyme is glucose oxidase.

51. The method of claim 32, wherein the organic-metal catalytic agent is disposed only in the interface.

52. The method of claim 32, wherein the organic-metal catalytic agent comprises manganese.

53. The method of claim 52, wherein the organic-metal catalytic agent comprises MnTPyP.

48. (canceled)